These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 21751166

  • 1. The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre.
    Rogowski F, Abdelrazek S, Szumowski P, Zonenberg A, Parfienczyk A, Sawicka A.
    Nucl Med Rev Cent East Eur; 2011; 14(1):9-15. PubMed ID: 21751166
    [Abstract] [Full Text] [Related]

  • 2. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
    Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C.
    Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
    [Abstract] [Full Text] [Related]

  • 3. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE, Michanek AM, Holmberg EC, Fink M.
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [Abstract] [Full Text] [Related]

  • 4. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA, Daykin J, Holder R, Sheppard MC.
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC, Zanin DE, Zweers EJ.
    Ned Tijdschr Geneeskd; 2002 Sep 28; 146(39):1837-41. PubMed ID: 12382370
    [Abstract] [Full Text] [Related]

  • 8. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M, Moka D, Reinholz U, Schmidt M, Schomäcker K, Schicha H, Wellner U.
    Nuklearmedizin; 2007 Sep 28; 46(3):77-84. PubMed ID: 17549318
    [Abstract] [Full Text] [Related]

  • 9. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA, Hermus AR, Ross HA, Buijs WC, Edelbroek MA, Bus JW, Corstens FH, Huysmans DA.
    J Nucl Med; 2004 Apr 28; 45(4):626-33. PubMed ID: 15073259
    [Abstract] [Full Text] [Related]

  • 10. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level.
    Adamali HI, Gibney J, O'Shea D, Casey M, McKenna TJ.
    Ir J Med Sci; 2007 Sep 28; 176(3):199-203. PubMed ID: 17632747
    [Abstract] [Full Text] [Related]

  • 11. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
    Walter MA, Schindler C, Christ-Crain M, Müller-Brand J, Müller B.
    Eur J Clin Invest; 2009 Jan 28; 39(1):51-7. PubMed ID: 19087129
    [Abstract] [Full Text] [Related]

  • 12. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.
    Erem C, Kandemir N, Hacihasanoglu A, Ersöz HO, Ukinc K, Kocak M.
    Endocrine; 2004 Oct 28; 25(1):55-60. PubMed ID: 15545707
    [Abstract] [Full Text] [Related]

  • 13. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
    Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A.
    Clin Endocrinol (Oxf); 1994 Jun 28; 40(6):803-6. PubMed ID: 8033373
    [Abstract] [Full Text] [Related]

  • 14. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L, De Palma D, Ceriani L, Vanoli P, Garancini S, Tordiglione M, Tarolo GL.
    Radiol Med; 2000 Dec 28; 100(6):480-3. PubMed ID: 11307510
    [Abstract] [Full Text] [Related]

  • 15. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen.
    Lewis A, Atkinson B, Bell P, Courtney H, McCance D, Mullan K, Hunter S.
    Ulster Med J; 2013 May 28; 82(2):85-8. PubMed ID: 24082285
    [Abstract] [Full Text] [Related]

  • 16. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O, Schulz G, Zimny M, Schreckenberger M, Zimny D, Wagenknecht G, Kaiser HJ, Dohmen BM, Bares R, Büll U.
    Nuklearmedizin; 1998 May 28; 37(3):83-9. PubMed ID: 9604227
    [Abstract] [Full Text] [Related]

  • 17. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
    Urbannek V, Schmidt M, Moka D, Hillger HW, Voth E, Wellner U, Schicha H.
    Nuklearmedizin; 2000 May 28; 39(4):108-12. PubMed ID: 10919161
    [Abstract] [Full Text] [Related]

  • 18. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
    Ruchała M, Sowiński J, Dolata M, Junik R, Gembicki M, Skiba A.
    Nucl Med Rev Cent East Eur; 2005 May 28; 8(1):28-32. PubMed ID: 15977144
    [Abstract] [Full Text] [Related]

  • 19. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.
    Regalbuto C, Marturano I, Condorelli A, Latina A, Pezzino V.
    J Endocrinol Invest; 2009 Feb 28; 32(2):134-8. PubMed ID: 19411811
    [Abstract] [Full Text] [Related]

  • 20. Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.
    Yu F, Zhang R, Zhang G, Meng Z, Liu X, He Y, Tan J, Wang R.
    Med Sci Monit; 2021 Jan 26; 27():e928796. PubMed ID: 33497370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.